Tune Therapeutics
Christina Jordan has a long and varied work experience. Christina began their career in 2000 as a Research Associate at Xencor. In 2006, they became an Associate at LUCAS & MERCANTI, LLP. From 2011 to 2013, they were an Associate Editor at the ABA Section of Litigation's Litigation News, then served as Editor in Chief, Executive Editor, and Team Editor at the same publication. In 2014, they became a Patent Portfolio Manager at the University of Washington Center for Commercialization. From 2017 to 2022, they were Director of Patents at Juno Therapeutics, Inc., and is currently Senior Director of Intellectual Property at Tune Therapeutics.
Christina Jordan attended the University of California, Los Angeles from 1995 to 1999, where they earned a B.S. in Microbiology and Women's Studies. Christina then attended Cardozo School of Law from 2003 to 2006.
This person is not in any teams
This person is not in any offices
Tune Therapeutics
1 followers
With its versatile and powerful TEMPO epigenomic control platform, Tune Therapeutics is pioneering a new therapeutic modality that can fine-tune any gene network and unlock the full power and potential of regenerative medicine. With deep experience and a passionate commitment to exploration and innovation, Tune is driving through an inflection point in the history of genetic medicine: from targeting a limited range of rare conditions, to addressing thousands of common and complex diseases for which no curative treatment is available.